GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2011

Phase III Levomilnacipran Study Fails to Meet Primary Endpoint in Major Depressive Disorder

  • Partners Forest Laboratories and Pierre Fabre Medicament said top-line results from a Phase III trial with levomilnacipran for the treatment of major depressive disorder (MDD) suggest the study has not met its primary endpoint. The data is in contrast to a previously completed, placebo-controlled Phase II trial, which showed that treatment using levomilnacipran led to statistically significant improvements in the Montgomery-Asberg Depression Rating Scale-Clinician-Rated (MADRS-CR).

    The newly reported Phase III study took the form of a placebo-controlled, flexible-dose trial involving 362 adult MDD patients. After a one-week run-in period patients were randomized to receive either 40-120 mg of levomilnacipran once daily, or placebo, for eight weeks plus an additional two-week down-taper period. Topline results found that although levomilnacipran consistently led to improvements in MADRS-CR scores over the course of the trial, the differences between drug treatment and placebo were not statistically significant.

    Two additional placebo-controlled Phase III studies with levomilnacipran in patients with MDD are ongoing. Results are expected during the second half of 2011.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?